Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.

MLA

Du, Danyu, et al. “Metabolic Dysregulation and Emerging Therapeutical Targets for Hepatocellular Carcinoma.” Acta Pharmaceutica Sinica. B, vol. 12, no. 2, Feb. 2022, pp. 558–80. EBSCOhost, https://doi.org/10.1016/j.apsb.2021.09.019.

APA

Du, D., Liu, C., Qin, M., Zhang, X., Xi, T., Yuan, S., Hao, H., & Xiong, J. (2022). Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharmaceutica Sinica. B, 12(2), 558–580. https://doi.org/10.1016/j.apsb.2021.09.019

Chicago

Du, Danyu, Chan Liu, Mengyao Qin, Xiao Zhang, Tao Xi, Shengtao Yuan, Haiping Hao, and Jing Xiong. 2022. “Metabolic Dysregulation and Emerging Therapeutical Targets for Hepatocellular Carcinoma.” Acta Pharmaceutica Sinica. B 12 (2): 558–80. doi:10.1016/j.apsb.2021.09.019.